Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Jane TchekalarovaLidia KortenskaNatasha IvanovaMilena AtanasovaPencho Marinov

Published in: Psychopharmacology (2019)

These findings support the value of agomelatine as an antidepressant that can adjust circadian homeostasis of motor activity and sleep/wake cycle in a CCL model.

Keyphrases

sleep quality
physical activity
poor prognosis
major depressive disorder
depressive symptoms
smoking cessation